MISC

国際誌
2020年2月

Diffusion-weighted MRI predicts the histologic response for neoadjuvant therapy in patients with pancreatic cancer: a prospective study (DIFFERENT trial).

Langenbeck's archives of surgery
  • Ken-Ichi Okada
  • Manabu Kawai
  • Seiko Hirono
  • Fumiyoshi Kojima
  • Kensuke Tanioka
  • Masaki Terada
  • Motoki Miyazawa
  • Yuji Kitahata
  • Yoshifumi Iwahashi
  • Masaki Ueno
  • Shinya Hayami
  • Shin-Ichi Murata
  • Toshio Shimokawa
  • Hiroki Yamaue
  • 全て表示

405
1
開始ページ
23
終了ページ
33
記述言語
英語
掲載種別
Scientific Journal
DOI
10.1007/s00423-020-01857-4

PURPOSE: Pre-operative prediction of histological response to neoadjuvant therapy aids decisions regarding surgical management of borderline resectable pancreatic cancer (BRPC). We elucidate correlation between pre-/post-treatment whole-tumor apparent diffusion coefficient (ADC) value and rate of tumor cell destruction. We newly verify whether post-treatment ADC value at the site of vascular contact predicts R0 resectability of BRPC. METHODS: We prospectively reviewed 28 patients with BRPC who underwent diffusion-weighted magnetic resonance imaging before neoadjuvant chemotherapy and surgery. Correlation between the percentage of tumor cell destruction and various parameters was analyzed. Strong parameters were assessed for their ability to predict therapeutic histological response and R0 resectability. RESULTS: Pre-/post-treatment whole-tumor ADC value correlated with tumor cell destruction rate by all parameters (R = 0.630/0.714, P < 0.001/< 0.0001). The post-treatment cutoff value of ADC at the site of vascular contact for discriminating histological response of tumor destruction of ≤ 50% and tumor destruction of > 50% was determined at 1.42 × 10-3 mm2/s. It predicts R0 with 88% sensitivity, 50% specificity, and 61% accuracy. For histological response, the post-treatment whole-tumor ADC cutoff value for discriminating between tumor destruction of ≤ 50% and tumor destruction of > 50% was determined at 1.40 × 10-3 mm2/s. It predicts histological response with 100% sensitivity, 81% specificity, and 89% accuracy. It predicts R0 with 88% sensitivity, 70% specificity, and 75% accuracy. CONCLUSIONS: Post-treatment whole-tumor ADC value may be a predictor of R0 resectability in patients with BRPC. Tumor cell destruction rate is indicated by the difference between pre-/post-treatment ADC values. This difference is strongly affected by the pre-treatment ADC value. The cutoff value of ADC at the site of vascular contact could not discriminate R0 resectability.

リンク情報
DOI
https://doi.org/10.1007/s00423-020-01857-4
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/31993737
ID情報
  • DOI : 10.1007/s00423-020-01857-4
  • PubMed ID : 31993737

エクスポート
BibTeX RIS